179 related articles for article (PubMed ID: 12803930)
1. Gaucher disease and the clinical experience with substrate reduction therapy.
Zimran A; Elstein D
Philos Trans R Soc Lond B Biol Sci; 2003 May; 358(1433):961-6. PubMed ID: 12803930
[TBL] [Abstract][Full Text] [Related]
2. Substrate reduction therapy: clinical evaluation in type 1 Gaucher disease.
Moyses C
Philos Trans R Soc Lond B Biol Sci; 2003 May; 358(1433):955-60. PubMed ID: 12803929
[TBL] [Abstract][Full Text] [Related]
3. Switching from imiglucerase to miglustat for the treatment of French patients with Gaucher disease type 1: a case series.
Serratrice C; Swiader L; Serratrice J
J Med Case Rep; 2015 Jun; 9():146. PubMed ID: 26100396
[TBL] [Abstract][Full Text] [Related]
4. Substrate reduction therapy of glycosphingolipid storage disorders.
Aerts JM; Hollak CE; Boot RG; Groener JE; Maas M
J Inherit Metab Dis; 2006; 29(2-3):449-56. PubMed ID: 16763917
[TBL] [Abstract][Full Text] [Related]
5. Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis.
Cox T; Lachmann R; Hollak C; Aerts J; van Weely S; Hrebícek M; Platt F; Butters T; Dwek R; Moyses C; Gow I; Elstein D; Zimran A
Lancet; 2000 Apr; 355(9214):1481-5. PubMed ID: 10801168
[TBL] [Abstract][Full Text] [Related]
6. Patients with Gaucher type 1: Switching from imiglucerase to miglustat therapy.
Canda E; Kose M; Kagnici M; Ucar SK; Sozmen EY; Coker M
Blood Cells Mol Dis; 2018 Feb; 68():180-184. PubMed ID: 28111116
[No Abstract] [Full Text] [Related]
7. Successful switch from enzyme replacement therapy to miglustat in an adult patient with type 1 Gaucher disease: a case report.
Giuffrida G; Lombardo R; Di Francesco E; Parrinello L; Di Raimondo F; Fiumara A
J Med Case Rep; 2016 Nov; 10(1):315. PubMed ID: 27821156
[TBL] [Abstract][Full Text] [Related]
8. Combination therapy in a patient with chronic neuronopathic Gaucher disease: a case report.
Ceravolo F; Grisolia M; Sestito S; Falvo F; Moricca MT; Concolino D
J Med Case Rep; 2017 Jan; 11(1):19. PubMed ID: 28103924
[TBL] [Abstract][Full Text] [Related]
9. Treatment of Gaucher's disease with OGT 918.
Mistry PK
Lancet; 2000 Aug; 356(9230):676-7. PubMed ID: 10968454
[No Abstract] [Full Text] [Related]
10. Gaucher disease: unmet treatment needs.
Mehta A
Acta Paediatr; 2008 Apr; 97(457):83-7. PubMed ID: 18339195
[TBL] [Abstract][Full Text] [Related]
11. An open-label, noncomparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24 months of treatment.
Pastores GM; Barnett NL; Kolodny EH
Clin Ther; 2005 Aug; 27(8):1215-27. PubMed ID: 16199246
[TBL] [Abstract][Full Text] [Related]
12. Substrate reduction therapy.
Platt FM; Jeyakumar M
Acta Paediatr; 2008 Apr; 97(457):88-93. PubMed ID: 18339196
[TBL] [Abstract][Full Text] [Related]
13. Changes of bone metabolism in seven patients with Gaucher disease treated consecutively with imiglucerase and miglustat.
Mikosch P; Reed M; Baker R; Holloway B; Berger L; Mehta AB; Hughes DA
Calcif Tissue Int; 2008 Jul; 83(1):43-54. PubMed ID: 18553043
[TBL] [Abstract][Full Text] [Related]
14. Imino sugar therapy for type 1 Gaucher disease.
Priestman DA; Platt FM; Dwek RA; Butters TD
Glycobiology; 2000 Nov; 10(11):iv-vi. PubMed ID: 11221677
[No Abstract] [Full Text] [Related]
15. Combined miglustat and enzyme replacement therapy in two patients with type 1 Gaucher disease: two case reports.
Amato D; Patterson MA
J Med Case Rep; 2018 Jan; 12(1):19. PubMed ID: 29373994
[TBL] [Abstract][Full Text] [Related]
16. Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement.
Elstein D; Dweck A; Attias D; Hadas-Halpern I; Zevin S; Altarescu G; Aerts JF; van Weely S; Zimran A
Blood; 2007 Oct; 110(7):2296-301. PubMed ID: 17609429
[TBL] [Abstract][Full Text] [Related]
17. Guidance on the use of miglustat for treating patients with type 1 Gaucher disease.
Weinreb NJ; Barranger JA; Charrow J; Grabowski GA; Mankin HJ; Mistry P
Am J Hematol; 2005 Nov; 80(3):223-9. PubMed ID: 16247743
[TBL] [Abstract][Full Text] [Related]
18. Neurologic improvement in a type 3 Gaucher disease patient treated with imiglucerase/miglustat combination.
Capablo JL; Franco R; de Cabezón AS; Alfonso P; Pocovi M; Giraldo P
Epilepsia; 2007 Jul; 48(7):1406-8. PubMed ID: 17433057
[TBL] [Abstract][Full Text] [Related]
19. Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease.
Elstein D; Hollak C; Aerts JM; van Weely S; Maas M; Cox TM; Lachmann RH; Hrebicek M; Platt FM; Butters TD; Dwek RA; Zimran A
J Inherit Metab Dis; 2004; 27(6):757-66. PubMed ID: 15505381
[TBL] [Abstract][Full Text] [Related]
20. The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement.
Cox TM; Aerts JM; Andria G; Beck M; Belmatoug N; Bembi B; Chertkoff R; Vom Dahl S; Elstein D; Erikson A; Giralt M; Heitner R; Hollak C; Hrebicek M; Lewis S; Mehta A; Pastores GM; Rolfs A; Miranda MC; Zimran A;
J Inherit Metab Dis; 2003; 26(6):513-26. PubMed ID: 14605497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]